Format

Send to

Choose Destination
Curr Oncol Rep. 2016 Jun;18(6):39. doi: 10.1007/s11912-016-0519-8.

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.

Author information

1
Department of Hematology, Shaare Zedek Medical Center, 12 Shmuel Bayit Street, Jerusalem, 91031, Israel.
2
Department of Hematology, Shaare Zedek Medical Center, 12 Shmuel Bayit Street, Jerusalem, 91031, Israel. rowe@jimmy.harvard.edu.
3
Technion, Israel Institute of Technology, Haifa, Israel. rowe@jimmy.harvard.edu.

Abstract

Patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have a dismal prognosis with less than 10 % of patients surviving 5 years. Most such patients cannot be rescued with currently available therapies, whatever the initial treatment they receive. Therefore, there is an urgent need for novel treatment options. Fortunately, over the past several years, an improved understanding of the biology of the disease has allowed the identification of rational molecular targets for therapeutic endeavors and the emergence of novel therapies has sparked great interest. This review will discuss the current treatment landscape for adult patients with relapsed and/or refractory ALL.

KEYWORDS:

Acute lymphoblastic leukemia; Blinatumomab; Chimeric antigen receptor-T; Relapsed/refractory

PMID:
27207612
DOI:
10.1007/s11912-016-0519-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center